Publications by authors named "M Barkati"

Claim this Profile
A
A randomized Phase II trial of High Dose-Rate (HDR) and Low Dose-Rate (LDR) brachytherapy as monotherapy in localized prostate cancer: analysis of initial arms of Canadian cancer trials group PR19 (NCT02960087).
G Morton, E Vigneault, M Barkati, J Helou, T M Niazi

Radiother Oncol· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Prostate-Specific Membrane Antigen PET-Guided Intensification of Salvage Radiotherapy After Radical Prostatectomy: A Phase 2 Randomized Clinical Trial.
Colin Belliveau, Fred Saad, Danny Duplan, Claire Petit, Guila Delouya, Maroie Barkati

JAMA Oncol· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
F-DCFPyL PSMA-PET/CT Versus MRI: Identifying the Prostate Cancer Region Most at Risk of Radiation Therapy Recurrence for Tumor Dose Escalation.
Colin Belliveau, Mustafa-Karim Benhacene-Boudam, Daniel Juneau, Nicolas Plouznikoff, Damien Olivié, Maroie Barkati

Pract Radiat Oncol· May 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
Hypofractionated Dose Escalation Radiotherapy for High-Risk Prostate Cancer: the survival analysis of the Prostate Cancer Study-5 (PCS-5), a GROUQ-led phase III trial.
Tamim Niazi, Abdenour Nabid, Talia Malagon, Steven Tisseverasinghe, Redouane Bettahar, Maroie Barkati

Eur Urol· March 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Adding 6 months of androgen deprivation therapy to postoperative radiotherapy for prostate cancer: a comparison of short-course versus no androgen deprivation therapy in the RADICALS-HD randomised controlled trial.
Chris C Parker, Noel W Clarke, Adrian D Cook, Howard Kynaston, Charles N Catton, Maroie Barkati

Lancet· June 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis